EMPAGUM: Effects of Empagliflozin on Gut Microbiota in Heart Failure With a Preserved Ejection Fraction

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT05584319

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
  • Zhijun Sun Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05584319
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05584319. Randomized; no masking; primary purpose treatment. Start 2022-12-15 (anticipated); primary completion 2024-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
EMPAGUM: Effects of Empagliflozin on Gut Microbiota in Heart Failure With a Preserved Ejection Fraction
Condition
Heart Failure
Intervention (Drug)
Empagliflozin 10 Mg
Lead sponsor
Zhijun Sun (class: other)

Record details

Record id
cardio:ct-nct05584319
Content hash
b760d0ce9d1409e89dd89cd0a2b1fad6d37febdd284aff153811fa24d72908b5